Search Results - Pascual, Tomas

Refine Results
  1. 1
    Intrinsic molecular subtypes of HER2+ breast cancer

    Intrinsic molecular subtypes of HER2+ breast cancer by Prat, Aleix, Pascual, Tomás, Adamo, Barbara

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

    Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer by Griguolo, Gaia, Pascual, Tomás, Dieci, Maria Vittoria, Guarneri, Valentina, Prat, Aleix

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

    De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance by Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases

    Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases by Laimito, Katerin Rojas, Gámez-Pozo, Angelo, Sepúlveda, Juan, Manso, Luis, López-Vacas, Rocío, Pascual, Tomás, Fresno Vara, Juan A, Ciruelos, Eva

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement by Colomer, Ramon, Saura, Cristina, Sánchez‐Rovira, Pedro, Pascual, Tomás, Rubio, Isabel T., Burgués, Octavio, Marcos, Lourdes, Rodríguez, César A., Martín, Miguel, Lluch, Ana

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

    Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer by Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2

    Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2 by Prat, Aleix, Brase, Jan Christoph, Cheng, Yuan, Nuciforo, Paolo, Paré, Laia, Pascual, Tomás, Martínez, Débora, Galván, Patricia, Vidal, Maria, Adamo, Barbara, Hortobagyi, Gabriel N., Baselga, José, Ciruelos, Eva

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer

    Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

    A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line... by Ciruelos, Eva, Apellániz‐Ruiz, María, Cantos, Blanca, Martinez‐Jáñez, Noelia, Bueno‐Muiño, Coralia, Echarri, Maria‐Jose, Enrech, Santos, Guerra, Juan‐Antonio, Manso, Luis, Pascual, Tomas, Dominguez, Cristina, Gonzalo, Juan‐Francisco, Sanz, Juan‐Luis, Rodriguez‐Antona, Cristina, Sepúlveda, Juan‐Manuel

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial by Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial by Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt... by Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study by Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodón, Jordi, Burgués, Octavio, Nuciforo, Paolo, Canes, Jordi, Paré, Laia, Dueñas, Marta, Vidal, Maria, Cejalvo, Juan Miguel, Perelló, Antonia, Llommbard-Cussac, Antonio, Dorca, Joan, Montaño, Alvaro, Pascual, Tomás, Oliveira, Mafalda, Ribas, Gloria, Rapado, Inmaculada, Prat, Aleix, Ciruelos, Eva

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    Gene expression profiles of breast cancer metastasis according to organ site

    Gene expression profiles of breast cancer metastasis according to organ site by Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

    Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy by Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, M. Vittoria, Pernas, Sonia, Gavila, Joaquin, Guarnieri, Valentina, Cortes, Javier, Villagrasa, Patricia, Chic, Núria, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galvan, Patricia, Carey, Lisa A., Perou, Charles M., Prat, Aleix

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

    Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer by Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

    Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy by Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., Prat, Aleix

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

    Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Stand... by Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade by Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: